Search Results for: Interleukin

December 4, 2019December 4, 2019

Interleukin 1 receptor antagonist gene variable number of tandem repeats polymorphism and cutaneous melanoma.

Melanoma Literature

Publication date: Dec 01, 2019 Immunity and cytokines serve crucial roles in cutaneous melanoma. The present study investigated whether a variable number tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist ... Read more

November 17, 2019November 17, 2019

Interleukin-18 Is a Prognostic Biomarker Correlated with CD8 T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma.

Melanoma Literature

Publication date: Nov 15, 2019 Interleukin-18 (IL-18) is a cytokine that enhances innate and adaptive immune responses. Although there are conflicting reports about the roles of IL-18 in melanoma progression, ... Read more

October 18, 2019October 18, 2019

Interleukin-22 May Be Biomarker to Monitor How Well RRMS Patients Respond to Therapy

Multiple Sclerosis News

Publication date: Oct 17, 2019 This post was originally published on this site The levels of the inflammatory molecule interleukin-22 (IL-22) may be used as a potential biomarker to evaluate ... Read more

October 4, 2019October 4, 2019

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Melanoma Literature

Publication date: Sep 30, 2019 Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been tested in advanced melanoma patients at various centers. We conducted a systematic review and ... Read more

August 20, 2019August 20, 2019

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.

Melanoma Literature

Publication date: Aug 17, 2019 Systemic immunotherapy with PD-1 inhibitors is established in the treatment of metastatic melanoma. However, up to 60% of patients do not show long-term benefit from ... Read more

July 5, 2019July 5, 2019

Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.

Multiple Sclerosis Literature

Publication date: Jun 19, 2019 Micro-RNAs (miRNAs) are evolving as biological markers for multiple sclerosis (MS) both in activity and remission. miR-96 is associated with remission, however, the exact mechanism ... Read more

July 3, 2019July 3, 2019

Association between interleukin-4 and interleukin-10 single nucleotide polymorphisms and multiple sclerosis among Iraqi patients.

Multiple Sclerosis Literature

Publication date: Jul 01, 2019 Multiple sclerosis (MS) is a neurodegenerative autoimmune disease, in which cytokines play a prominent role. Among these cytokines are interleukin-4 (IL-4) and IL-10, which have ... Read more

June 28, 2019June 28, 2019

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma News

Publication date: Jun 27, 2019 This is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently ... Read more

June 28, 2019June 28, 2019

Pre-clinical investigation of the synergy effect of interleukin-12 gene-electro-transfer during partially irreversible electropermeabilization against melanoma.

Melanoma Literature

Publication date: Jun 26, 2019 Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, ... Read more

June 7, 2019

Investigators Are Assessing an Experimental Interleukin-2 Drug in Patients With Metastatic Melanoma

Melanoma News

Publication date: Jun 04, 2019 A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2 -based drug vs nivolumab alone in patients with metastatic melanoma ... Read more